head and neck cancer
Cofactor Genomics Immunotherapy Response Test Nabs Medicare Coverage
The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
Naveris, MSK Begin Phase II Clinical Study in MRD-Positive Head and Neck Cancer
The company's blood-based NavDx assay will be used to identify patients with molecular relapse who are eligible for additional treatment.
Investigators published early case control data in a recent preprint showing remarkable sensitivity and are now considering their best options for further validation.
CMS Designates NavDx Test for HPV-Driven Cancer as ADLT
The test received Medicare coverage in 2023 for assessing molecular residual disease in patients with a history of HPV-driven head and neck cancer.